Emergency Department, Women's and Children's Hospital, University of Adelaide, North Adelaide, South Australia, Australia.
Emergency Department, Sidra Medical and Research Center, Doha, Qatar.
Emerg Med J. 2019 Apr;36(4):225-230. doi: 10.1136/emermed-2018-207929. Epub 2018 Nov 27.
To determine the variability of primary and secondary outcomes used in trials of intravenous bronchodilators in children with acute severe paediatric asthma.
Systematic search of MEDLINE, EMBASE, Cochrane CENTRAL and the WHO International Clinical Trials Registry Platform for randomised trials in children (less than18 years) with acute severe paediatric asthma comparing intravenous bronchodilator therapy to another treatment. Initial search was performed on 7 January 2016 with an updated search performed on 6 September 2018. Primary and secondary outcomes were collated.
We identified 35 published papers and four registered study protocols. 56 primary outcomes were found, the most common being a clinical asthma score (23/56; 41%). Other identified primary outcomes included bedside tests of respiratory function (11/56; 20%) and measures of length of stay (9/56; 16%). There were a total of 60 different secondary outcomes, the most common were various length of stay measures (24/60; 40%) and adverse events (11/60; 18%).
Studies comparing intravenous treatment modalities for children with acute severe paediatric asthma exhibit great variation in the type, number and timing of outcome measures used. There are no patient or family-specific outcomes reported. There is a need to develop international consensus.
CRD42017055331.
确定急性重度儿童哮喘患儿静脉支气管扩张剂治疗试验中使用的主要和次要结局的变异性。
系统检索 MEDLINE、EMBASE、Cochrane 中心和世界卫生组织国际临床试验注册平台上比较静脉支气管扩张剂治疗与其他治疗的急性重度儿童哮喘儿童的随机试验。初始搜索于 2016 年 1 月 7 日进行,更新搜索于 2018 年 9 月 6 日进行。整理了主要和次要结局。
我们确定了 35 篇已发表的论文和 4 份注册研究方案。共发现 56 个主要结局,最常见的是临床哮喘评分(23/56;41%)。其他确定的主要结局包括床边呼吸功能测试(11/56;20%)和住院时间测量(9/56;16%)。共有 60 个不同的次要结局,最常见的是各种住院时间测量(24/60;40%)和不良事件(11/60;18%)。
比较急性重度儿童哮喘患儿静脉治疗方法的研究在使用的结局测量类型、数量和时间方面存在很大差异。没有报告针对患者或家庭的特定结局。有必要制定国际共识。
CRD42017055331。